Ignite Creation Date:
2024-05-06 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 12:44 PM
Study NCT ID:
NCT03504163
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2018-04-11
Brief Title:
Pembrolizumab MK-3475 and Bacillus Calmette-Guérin BCG as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer NMIBC and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma NMI-UTUC
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-27
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-04
Completion Date Type:
ESTIMATED
First Submit Date:
2018-04-11
First Submit QC Date:
April 12 2018
Study First Post Date:
2018-04-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-29
Last Update Post Date:
2024-06-25
Last Update Post Date Type:
ACTUAL